Risk factors for taxane-induced peripheral neuropathy in patients with breast cancer
CONCLUSION: Cumulative dose, BMI, BSA, and hypocalcemia are all risk factors for overall TIPN, whereas cumulative dose and BSA are risk factors for moderate-severe TIPN. Patients with breast cancer who have high BMI, large BSA, hypocalcemia, and large cumulative dose may be at risk of TIPN, and intervention measures must be actively carried out for them.PMID:36658674 | DOI:10.1111/ajco.13923 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 19, 2023 Category: Cancer & Oncology Authors: Cuilv Liang Yin Zhang Qi Ying Chen Wen Fa Chen Ming Zhu Chen Source Type: research
Risk factors for taxane-induced peripheral neuropathy in patients with breast cancer
CONCLUSION: Cumulative dose, BMI, BSA, and hypocalcemia are all risk factors for overall TIPN, whereas cumulative dose and BSA are risk factors for moderate-severe TIPN. Patients with breast cancer who have high BMI, large BSA, hypocalcemia, and large cumulative dose may be at risk of TIPN, and intervention measures must be actively carried out for them.PMID:36658674 | DOI:10.1111/ajco.13923 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 19, 2023 Category: Cancer & Oncology Authors: Cuilv Liang Yin Zhang Qi Ying Chen Wen Fa Chen Ming Zhu Chen Source Type: research
The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
ConclusionOur results preliminarily show a survival benefit of neoadjuvant sintilimab combined with chemotherapy in locally advanced ESCC. (Source: Frontiers in Immunology)
Source: Frontiers in Immunology - January 19, 2023 Category: Allergy & Immunology Source Type: research
Pirfenidone suppressed triple-negative breast cancer metastasis by inhibiting the activity of the TGF- β/SMAD pathway
In this study, we assessed the efficacy of Pirfenidone (PFD), an FDA-approved medication for the treatment of idiopathic pulmonary fibrosis, on TNBC cells as well as its anti-tumour effects in xenograft tumour model. PFD inhibited in a dose-dependent manner breast cancer cell proliferation, migration, and invasion, while promoted their apoptosis in vitro. PFD also suppressed TGF-β-induced activation of Smad signalling pathway and expression level of EMT-inducing transcription factors (e.g. SNAI2, TWIST1, ZEB1) as well as the mesenchymal genes such as VIMENTIN and N-Cadherin. On the contrary, the expression level of epithe...
Source: Molecular Medicine - January 18, 2023 Category: Molecular Biology Authors: Daiqin Luo Xianlin Zeng Shuling Zhang Daohong Li Zhimei Cheng Yun Wang Jinhua Long Zuquan Hu Shiqi Long Jing Zhou Shuai Zhang Zhu Zeng Source Type: research
Pirfenidone suppressed triple-negative breast cancer metastasis by inhibiting the activity of the TGF- β/SMAD pathway
In this study, we assessed the efficacy of Pirfenidone (PFD), an FDA-approved medication for the treatment of idiopathic pulmonary fibrosis, on TNBC cells as well as its anti-tumour effects in xenograft tumour model. PFD inhibited in a dose-dependent manner breast cancer cell proliferation, migration, and invasion, while promoted their apoptosis in vitro. PFD also suppressed TGF-β-induced activation of Smad signalling pathway and expression level of EMT-inducing transcription factors (e.g. SNAI2, TWIST1, ZEB1) as well as the mesenchymal genes such as VIMENTIN and N-Cadherin. On the contrary, the expression level of epithe...
Source: J Cell Mol Med - January 18, 2023 Category: Molecular Biology Authors: Daiqin Luo Xianlin Zeng Shuling Zhang Daohong Li Zhimei Cheng Yun Wang Jinhua Long Zuquan Hu Shiqi Long Jing Zhou Shuai Zhang Zhu Zeng Source Type: research
Pirfenidone suppressed triple-negative breast cancer metastasis by inhibiting the activity of the TGF- β/SMAD pathway
In this study, we assessed the efficacy of Pirfenidone (PFD), an FDA-approved medication for the treatment of idiopathic pulmonary fibrosis, on TNBC cells as well as its anti-tumour effects in xenograft tumour model. PFD inhibited in a dose-dependent manner breast cancer cell proliferation, migration, and invasion, while promoted their apoptosis in vitro. PFD also suppressed TGF-β-induced activation of Smad signalling pathway and expression level of EMT-inducing transcription factors (e.g. SNAI2, TWIST1, ZEB1) as well as the mesenchymal genes such as VIMENTIN and N-Cadherin. On the contrary, the expression level of epithe...
Source: J Cell Mol Med - January 18, 2023 Category: Molecular Biology Authors: Daiqin Luo Xianlin Zeng Shuling Zhang Daohong Li Zhimei Cheng Yun Wang Jinhua Long Zuquan Hu Shiqi Long Jing Zhou Shuai Zhang Zhu Zeng Source Type: research
Apatinib combined with trastuzumab and albumin-bound paclitaxel for treatment of HER2+ breast cancer with brain metastases resistant to anti-HER2 TKIs: A case report
Oncol Lett. 2022 Dec 20;25(2):56. doi: 10.3892/ol.2022.13642. eCollection 2023 Feb.ABSTRACTAlthough human epidermal growth factor receptor 2 (HER2)-targeted therapy significantly improves the prognosis of patients with HER2-positive breast cancer, most patients with advanced breast cancer eventually progress due to drug resistance. At present, there is no standard treatment after patients become resistant to HER2-targeted therapy. Previous studies have indicated that anti-angiogenesis drugs have potential efficacy in the treatment of advanced breast cancer. The present study reported on a case of a pretreated patient with ...
Source: Oncology Letters - January 16, 2023 Category: Cancer & Oncology Authors: Jiayi Huang Xiao Chen Jinfeng Guo Lin Song Yanxi Mu Han Zhao Caiwen Du Source Type: research
Molecules, Vol. 28, Pages 880: Research and Application of Kupffer Cell Thresholds for BSA Nanoparticles
In this study, the delivery efficiency of ABP was improved by using blank nanoparticles to saturate Kupffer cells, which provided a new approach to studying the Kupffer cell saturation threshold and thus a new scheme for improving the curative effect of ABP. (Source: Molecules)
Source: Molecules - January 16, 2023 Category: Chemistry Authors: Huanhuan Guo Zongguang Tai Fang Liu Jing Tian Nan Ding Zhongjian Chen Shen Gao Tags: Article Source Type: research
Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04)
CONCLUSION: Nab-PTX plus T-mab and P-mab induced a high pCR rate in HER2-positive BC, particularly in the HER2-subtype. Given that AEs are acceptable, this regimen is safe and acceptable as NAC for HER2-positive BC.PMID:36609911 | DOI:10.1007/s12282-022-01425-2 (Source: Breast Cancer)
Source: Breast Cancer - January 7, 2023 Category: Cancer & Oncology Authors: Manabu Futamura Kazuhiro Ishihara Yasuko Nagao Atsuko Ogiso Yoshimi Niwa Takumi Nakada Yoshihiro Kawaguchi Ai Ikawa Iwao Kumazawa Ryutaro Mori Mai Kitazawa Yoshiki Hosono Masashi Kuno Mana Kawajiri Akira Nakakami Makoto Takeuchi Akemi Morikawa Yoshihisa T Source Type: research
Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04)
CONCLUSION: Nab-PTX plus T-mab and P-mab induced a high pCR rate in HER2-positive BC, particularly in the HER2-subtype. Given that AEs are acceptable, this regimen is safe and acceptable as NAC for HER2-positive BC.PMID:36609911 | DOI:10.1007/s12282-022-01425-2 (Source: Breast Cancer)
Source: Breast Cancer - January 7, 2023 Category: Cancer & Oncology Authors: Manabu Futamura Kazuhiro Ishihara Yasuko Nagao Atsuko Ogiso Yoshimi Niwa Takumi Nakada Yoshihiro Kawaguchi Ai Ikawa Iwao Kumazawa Ryutaro Mori Mai Kitazawa Yoshiki Hosono Masashi Kuno Mana Kawajiri Akira Nakakami Makoto Takeuchi Akemi Morikawa Yoshihisa T Source Type: research
